Posts by Constance

4 weeks ago

EGL-003 Phase 1 SAD Study – Data Results and KOL Perspective Webcast

Date : 1 October 2026 Location : Virtual (on-demand webcast) Egle Therapeutics will host a webcast reviewing new Phase 1 data for EGL-003, our Treg-selective IL-2 program in atopic dermatitis,…

4 weeks ago

Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study

EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without amplification of conventional CD4, CD8 or NK cell populations. Biomarker…

4 weeks ago

EADV Congress 2026

Egle Therapeutics at EADV 2026 Dates : 30 September – 3 October 2026 Location : Vienna, Austria Egle Therapeutics will present new Phase 1 data for EGL-003 as an ePoster…

1 month ago

Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna

Egle to share clinical data on EGL-003, the company’s most advanced Treg-selective IL-2 agonist for atopic dermatitis Paris, France, (September 15, 2026) – Egle Therapeutics (“Egle”), a clinical-stage biotechnology company…

8 months ago

Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer

Paris, France, March 2, 2026 – Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with…

10 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Paris, France, Jan. 7, 2026 – Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with…

11 months ago

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

Paris, France, Dec. 1, 2025 – Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing…

1 year ago

International Congress of Immunology – IUIS 2025

Dates : 17 – 22 August 2025 Location : Vienna, Austria Several representatives from our laboratory will have the pleasure of participating in the 19th International Congress of Immunology, organized…

1 year ago

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

Paris, France, June 10th 2025 – Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at…